The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an ...

Gilead Sciences’ Kite Pharma unit is closing on approval of ... formal approval by the regulator in the coming weeks. Known as Tecartus in the US, this is the third CAR-T therapy to be ...

Kite, a Gilead company GLD, announced that the Food & Drug Administration granted accelerated approval to Tecartus, a CAR T cell therapy for the treatment of adult patients with mantle cell lymphoma.

Kite Pharma is flying high with the addition of ... registered a 1% year-over-year drop in sales and its counterpart Tecartus gained just 2%. At the time, Gilead linked the stagnation to ...